Zami Aberman
2017
In 2017, Zami Aberman earned a total compensation of $3.6M as Co, CEO at Pluristem Therapeutics, a 402% increase compared to previous year.
Compensation breakdown
| Salary | $492,950 |
|---|---|
| Stock Awards | $3,050,000 |
| Other | $16,462 |
| Total | $3,559,412 |
Aberman received $3.1M in stock awards, accounting for 86% of the total pay in 2017.
Aberman also received $493K in salary and $16.5K in other compensation.
Rankings
In 2017, Zami Aberman's compensation ranked 2,957th out of 14,666 executives tracked by ExecPay. In other words, Aberman earned more than 79.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,957 out of 14,666 | 80th |
Division Manufacturing | 1,017 out of 5,772 | 82nd |
Major group Chemicals And Allied Products | 272 out of 2,075 | 87th |
Industry group Drugs | 207 out of 1,731 | 88th |
Industry Biological Products, Except Diagnostic Substances | 38 out of 313 | 88th |
Source: SEC filing on April 3, 2018.
Aberman's colleagues
We found two more compensation records of executives who worked with Zami Aberman at Pluristem Therapeutics in 2017.
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019